Trial Profile

Short-term Combined Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection and/or Early Treatment, Who do Not Fulfil IWCLL Treatment Criteria

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 10 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Jun 2023 Results (n=118) clinically validating the predictive performance of CLL-TIM identifying newly diagnosed patients with high risk of infection and/or treatment as part of this study, presented at the 28th Congress of the European Haematology Association
10 Feb 2020 Status changed from not yet recruiting to recruiting.
06 Nov 2019 According to trial design released in 61st Annual Meeting and Exposition of the American Society of Hematology, first patient enrollment in trial was planned for September 2019 and primary outcome expected in 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com